Nesrine EBRAHIM1, Eman EHSAN2, Eman Abd EL GHANY2, Dina SABRY3, Ashraf SHAMAA4
BIOCELL, Vol.43, No.1, pp. 21-28, 2019, DOI:10.32604/biocell.2019.06111
Abstract The neonatal hypoxic–ischemic encephalopathy (HIE) is an important cause of neurological morbidity and
mortality in neonates. Cell therapy is considered a promising method for treating severe neurological disorders such as
this one. Stem cells have the capacity for self-renewal and differentiation into certain cell lineages. The present study was
aimed to find out the most beneficial route of bone marrow-derived mesenchymal stem cells (BMSCs) administration
for the attenuation of experimentally induced HIE in neonatal rats. Sixty neonatal rats were divided randomly into
four groups. Group 1: control group. Group 2: rats were exposed to… More >